The last patient of the 16 patient Phase 1 Renal Trial with RVX-208 was enrolled on September 10, and the trial is now listed as "Completed." Last date of data collection was September 16th. Healthy or renally impaired patients were dosed for just 7 days in this trial. In addition to general safety assessment, this trial was looking at drug pharmacokinetics as well as plasma protein changes via the SomaLogic SOMAscan system. My guess is that the dosing, blood collection and safety assessement portion of the trial is completed, but that it will take a bit more time for completion of the pharmacokinetic and SOMAscan portion of the analysis.

BearDownAZ